Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.

Kim N, Sohn MJ, Koshino H, Kim EH, Kim WG.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):83-6. doi: 10.1016/j.bmcl.2013.11.071.

PMID:
24332629
2.

Verrulactones A and B, new inhibitors of Staphylococcus aureus enoyl-ACP reductase produced by Penicillium verruculosum F375.

Kim N, Sohn MJ, Kim CJ, Kwon HJ, Kim WG.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2503-6. doi: 10.1016/j.bmcl.2012.02.001.

PMID:
22377515
3.

Verrulactones D and E with unprecedented skeletons, new inhibitors of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.

Kim N, Sohn MJ, Koshino H, Kim WG.

J Antibiot (Tokyo). 2016 Feb;69(2):114-8. doi: 10.1038/ja.2015.86. No abstract available.

PMID:
26306815
4.

Vinaxanthone, a new FabI inhibitor from Penicillium sp.

Zheng CJ, Sohn MJ, Kim WG.

J Antimicrob Chemother. 2009 May;63(5):949-53. doi: 10.1093/jac/dkp058.

5.

Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.

Kim YG, Seo JH, Kwak JH, Shin KJ.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4481-6. doi: 10.1016/j.bmcl.2015.08.077.

PMID:
26343826
6.

Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).

Sampson PB, Picard C, Handerson S, McGrath TE, Domagala M, Leeson A, Romanov V, Awrey DE, Thambipillai D, Bardouniotis E, Kaplan N, Berman JM, Pauls HW.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5355-8. doi: 10.1016/j.bmcl.2009.07.129.

PMID:
19682901
7.

Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.

Zheng CJ, Sohn MJ, Lee S, Kim WG.

PLoS One. 2013 Nov 28;8(11):e78922. doi: 10.1371/journal.pone.0078922.

8.

Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.

Kwon YJ, Fang Y, Xu GH, Kim WG.

Biol Pharm Bull. 2009 Dec;32(12):2061-4.

9.

Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).

Mehboob S, Song J, Hevener KE, Su PC, Boci T, Brubaker L, Truong L, Mistry T, Deng J, Cook JL, Santarsiero BD, Ghosh AK, Johnson ME.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1292-6. doi: 10.1016/j.bmcl.2015.01.048.

10.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

11.

Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.

Takahata S, Iida M, Yoshida T, Kumura K, Kitagawa H, Hoshiko S.

J Antibiot (Tokyo). 2007 Feb;60(2):123-8.

PMID:
17420562
12.

Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.

Schiebel J, Chang A, Shah S, Lu Y, Liu L, Pan P, Hirschbeck MW, Tareilus M, Eltschkner S, Yu W, Cummings JE, Knudson SE, Bommineni GR, Walker SG, Slayden RA, Sotriffer CA, Tonge PJ, Kisker C.

J Biol Chem. 2014 Jun 6;289(23):15987-6005. doi: 10.1074/jbc.M113.532804.

13.

Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.

Kwon YJ, Kim HJ, Kim WG.

Biol Pharm Bull. 2015;38(5):715-21. doi: 10.1248/bpb.b14-00824.

14.
15.

4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.

Kitagawa H, Kumura K, Takahata S, Iida M, Atsumi K.

Bioorg Med Chem. 2007 Jan 15;15(2):1106-16.

PMID:
17095231
16.

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2007 Apr;51(4):1580-1. No abstract available.

17.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.

J Med Chem. 2002 Jul 18;45(15):3246-56.

PMID:
12109908
18.

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, Payne DJ, Rittenhouse SF, Moore TD, DeWolf WE Jr, Keller PM, Qiu X, Janson CA, Vaidya K, Fosberry AP, Smyth MG, Jaworski DD, Slater-Radosti C, Huffman WF.

Bioorg Med Chem Lett. 2001 Sep 3;11(17):2241-4.

PMID:
11527706
19.

The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, Soulama-Mouze C.

Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. doi: 10.1128/AAC.01248-10.

20.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
Items per page

Supplemental Content

Support Center